O-L, single-arm, Phase 2 study of pts postRNU and + for FGF/FGFR alterations now underway led by @AndreaNecchi . Rx w. INCB054828 as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma #EAU18
O-L, single-arm, Phase 2 study of pts postRNU and + for FGF/FGFR alterations now underway led by @AndreaNecchi . Rx w. INCB054828 as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma #EAU18